• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Nov. 19, 2020

View Archived Issues
Coronavirus, antibody illustration

Dueling quantitative COVID-19 neutralizing antibody tests roll out as vaccines approach completion

Hot on the heels of news that two vaccines for COVID-19 are nearing market readiness, two companies have broken away from the pack of assay manufacturers to offer quantitative antibody tests that can verify whether the vaccines provide effective, lasting protection. Siemens Healthineers and Imanis Life Sciences both claim to be first to develop scalable, quantitative neutralizing antibody tests. Read More
Probeam device, Cincinnati Children's/UC Health Proton Therapy Center

Varian sees first patient treated in study of FLASH therapy for cancer

Varian Medical Systems Inc. revealed that the first clinical trial of FLASH therapy has kicked off, with the initial treatment taking place at the Cincinnati Children's/UC Health Proton Therapy Center. The study, which saw the first patient treated this week, involves the investigational use of Varian's Probeam particle accelerator modified to enable radiation therapy delivery at ultra-high dose rates. Read More
US-health-flag-medicare.png

Pandemic imposing no drag on U.S. government scrutiny of speaker programs

The casual observer may think that physician speaker programs sponsored by makers of drugs and medical devices have drawn less attention from U.S. federal attorneys, but reality has failed to meet that expectation. Mark Gardner, managing attorney of Gardner Law of Stillwater, Minn., said on a Nov. 19 webinar that “there’s a lot coming through right now in terms of settlements,” including a settlement with a drug maker that sent the company into bankruptcy. Read More
Illustration of device in body

Sequana Medical reports positive interim data from pivotal Alfapump trial

Sequana Medical NV scored a U.S. FDA breakthrough device designation last year for its fully implanted wireless device that automatically pumps fluids from the abdomen into the bladder. Now, it has released positive interim safety and efficacy data on that device, known as Alfapump, in the treatment of patients with recurrent or refractory ascites due to liver cirrhosis. Read More
US-capital-washington-congress-government.png

Stock sales amid vaccine news renew calls for 10b5-1 ‘cooling-off’ period

Concerns about biopharma executives profiting from stock sales aligned with releases of promising COVID-19 vaccine results could result in Congress requiring a cooling-off period for executives’ 10b5-1 plans that provide a safe harbor to insider trading. Testifying in a Nov. 17 hearing before the Senate Banking Committee, SEC Chair Jay Clayton suggested a mandatory period of four to six months between implementing or materially changing a 10b5-1 plan and the first allowed stock sale. He added that the cooling-off period should at least cover a full quarter. Read More

HHS unveils pilot for Cue’s POC test

The latest global regulatory news, changes and updates affecting medical devices and technologies. Read More

Appointments and advancements for Nov. 19, 2020

New hires and promotions in the med-tech industry, including: Abcellera, Dcn Dx, Electromed, Heartflow, Natera, Quanterix. Read More

Financings for Nov. 19, 2020

Med-tech firms raising money in public or private financings, including: CB2 Insights, Closedloop.ai, Stryker. Read More

In the clinic for Nov. 19, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Dariohealth, Geneoscopy, Sequana Medical, Teleflex. Read More

Other news to note for Nov. 19, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abcellera, Apiject, Biontech, Biotia, Daxor, Dcn Dx, Debogy Molecular, Delmar Gardens, Doc.ai, Epic Sciences, Fluidigm, Fujifilm, Jadak Technologies, Key Surgical, Lundquist Institute, Martis Capital, Medsphere Systems, Micro-Office Systems, Paras Defence & Space Technologies, Pear Therapeutics, Predictmedix, Qiagen, Scapa Healthcare, Steris, Telememory, Trianni, Twist Bioscience, Ucb Biopharma. Read More

BioWorld MedTech’s Diagnostics Extra for Nov. 19, 2020

Keeping you up to date on recent developments in diagnostics, including: Imaging methods reveal underlying cause of unexplained heart attack; Questionnaire predicts people at high risk for heart disease; Bias skews tally on imaging diagnostic test accuracy studies. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 20, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe